Literature DB >> 30131260

Repeated attacks of type III hereditary angioedema with factor XII mutation during pregnancy.

S Feray1, O Fain2, G Kayem3, N Sabourdin1, I Constant1, A Rigouzzo4.   

Abstract

In type III hereditary angioedema (HAE type III), the phenotype is the same as type I and type II disease, but the level and function of C1-esterase inhibitor (C1-INH) is normal. Hereditary angioedema type III has been described as an oestrogen-sensitive form because it can be triggered or aggravated by exposure to high oestrogen levels as seen during pregnancy, especially when associated with Factor XII mutation. This case report describes the evolution and management of repeated angioedema attacks during pregnancy in a woman with HAE, with normal levels and function of C1-INH (type III); and a mis-sense mutation of factor XII. The physiopathology and genetic features, the unpredictability of clinical manifestations and the management during pregnancy and delivery are discussed.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Factor XII mutation; Hereditary angioedema; Pregnancy

Mesh:

Substances:

Year:  2018        PMID: 30131260     DOI: 10.1016/j.ijoa.2018.07.003

Source DB:  PubMed          Journal:  Int J Obstet Anesth        ISSN: 0959-289X            Impact factor:   2.603


  3 in total

1.  Acute Presentation of Undiagnosed Hereditary Angioedema of the Larynx: Averting Death.

Authors:  Nikhil Rajan; Vidhu Sharma; Sourabha Kumar Patro; Amit Goyal
Journal:  Turk Arch Otorhinolaryngol       Date:  2020-12-01

2.  Pregnancy in Patients With Hereditary Angioedema and Normal C1 Inhibitor.

Authors:  Natalia Gabriel; Fernanda Marcelino; Mariana P L Ferriani; L Karla Arruda; Regis A Campos; Rozana F Gonçalves; Herberto Chong-Neto; Nelson Rosario Filho; Solange O R Valle; Joao B Pesquero; Anete S Grumach
Journal:  Front Allergy       Date:  2022-02-17

Review 3.  High Estrogen States in Hereditary Angioedema: a Spectrum.

Authors:  Maansi Kulkarni; Jeffrey B Travers; Craig Rohan
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-01       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.